HK1099764A1 - Quinoxalines useful as inhibitors of protein kinases - Google Patents
Quinoxalines useful as inhibitors of protein kinasesInfo
- Publication number
- HK1099764A1 HK1099764A1 HK07107067.6A HK07107067A HK1099764A1 HK 1099764 A1 HK1099764 A1 HK 1099764A1 HK 07107067 A HK07107067 A HK 07107067A HK 1099764 A1 HK1099764 A1 HK 1099764A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- protein kinases
- quinoxalines
- useful
- quinoxalines useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52684303P | 2003-12-04 | 2003-12-04 | |
PCT/US2004/040777 WO2005056547A2 (fr) | 2003-12-04 | 2004-12-03 | Quinoxalines utiles comme inhibiteurs des proteines kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1099764A1 true HK1099764A1 (en) | 2007-08-24 |
Family
ID=34676666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07107067.6A HK1099764A1 (en) | 2003-12-04 | 2007-07-03 | Quinoxalines useful as inhibitors of protein kinases |
Country Status (8)
Country | Link |
---|---|
US (2) | US7592340B2 (fr) |
EP (1) | EP1694671A2 (fr) |
JP (2) | JP2007513184A (fr) |
CN (1) | CN1902193B (fr) |
AU (1) | AU2004297235A1 (fr) |
CA (1) | CA2548172A1 (fr) |
HK (1) | HK1099764A1 (fr) |
WO (1) | WO2005056547A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080049767A (ko) * | 2005-08-26 | 2008-06-04 | 라보라뚜와르 세로노 에스. 에이. | 피라진 유도체 및 pi3k 억제제로서의 용도 |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (fr) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal |
EP1957487A1 (fr) | 2005-11-11 | 2008-08-20 | AEterna Zentaris GmbH | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
BRPI0808523A2 (pt) | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | Inibidores de pim cinase e métodos de seu uso |
AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
EP2282995B1 (fr) * | 2008-05-23 | 2015-08-26 | Novartis AG | Dérivés de quinoléines et de quinoxalines en tant qu' inhibiteurs de protéine tyrosine kinases |
FR2933977B1 (fr) * | 2008-07-18 | 2013-04-26 | Centre Nat Rech Scient | Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives |
ES2551900T3 (es) | 2008-09-02 | 2015-11-24 | Novartis Ag | Derivados de picolinamida como inhibidores de cinasa |
EP2396004A4 (fr) * | 2009-02-11 | 2012-07-25 | Reaction Biology Corp | Inhibiteurs de kinase sélectifs |
HUE024874T2 (en) * | 2009-09-03 | 2016-02-29 | Bioenergenix | Heterocyclic compounds for inhibiting PASK |
WO2011029804A1 (fr) | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibiteurs de jak |
EP2489663A1 (fr) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Composés en tant qu'inhibiteurs de la syk kinase |
EP2508184A1 (fr) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation |
US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
US9120785B2 (en) | 2011-05-10 | 2015-09-01 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as Syk inhibitors |
CA2834604A1 (fr) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Aminopyrimidines en tant qu'inhibiteurs de syk |
WO2013052391A1 (fr) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide |
EP2763975B1 (fr) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide |
EP2763976B1 (fr) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide |
AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
ES2860299T3 (es) | 2012-04-24 | 2021-10-04 | Vertex Pharma | Inhibidores de DNA-PK |
AU2013264831B2 (en) | 2012-05-21 | 2016-04-21 | Novartis Ag | Novel ring-substituted N-pyridinyl amides as kinase inhibitors |
SI2970218T1 (sl) | 2013-03-12 | 2019-04-30 | Vertex Pharmaceuticals Inc. | DNA-PK inhibitorji |
RS60426B1 (sr) | 2013-10-17 | 2020-07-31 | Vertex Pharma | Kokristali (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)hinolin-4-karboksamida i njihovi deuterisani derivati kao inhibitori dnk-pk |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
US9822107B2 (en) | 2013-12-20 | 2017-11-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015094997A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique |
US9775839B2 (en) | 2014-03-13 | 2017-10-03 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
US10432056B2 (en) * | 2016-04-26 | 2019-10-01 | Ford Global Technologies, Llc | Electric machine rotor endcap |
CA3038657A1 (fr) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une combinaison d'agents endommageant l'adn et d'inhibiteurs de la dna-pk |
CN113943288A (zh) * | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
JPS5476599A (en) * | 1977-11-30 | 1979-06-19 | Mitsubishi Yuka Yakuhin Kk | Pyrimidoquinoxaline derivative*its manufacture and allergic asthma thrapeutic medicine |
DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | 5−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
AU9049391A (en) * | 1990-12-20 | 1992-07-22 | Warner-Lambert Company | 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2079982A1 (fr) * | 1991-10-07 | 1993-04-08 | Stephen E. De Laszlo | Derives de substitution de la pyrazino¬2,3-d|pyrimidone, antagonistes de l'angiotensine ii |
ES2219670T3 (es) * | 1994-11-10 | 2004-12-01 | Millennium Pharmaceuticals, Inc. | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. |
IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU726590B2 (en) | 1996-11-15 | 2000-11-09 | Darwin Discovery Limited | Bicyclic aryl carboxamides and their therapeutic use |
ATE267176T1 (de) * | 1997-09-01 | 2004-06-15 | Kyorin Seiyaku Kk | 6,7-asymmetrisch disubstituierte chinoxalincarbonsäurederivate, additionssalze davon und verfahren zur herstellung von beiden |
US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
ATE245641T1 (de) * | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
EP1086085A1 (fr) | 1998-06-12 | 2001-03-28 | Vertex Pharmaceuticals Incorporated | INHIBITEURS DE p38 |
EP1105394A1 (fr) * | 1998-08-21 | 2001-06-13 | Du Pont Pharmaceuticals Company | Isoxazolo 4,5-d]pyrimidines comme antagonistes du crf |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU1223400A (en) | 1998-10-22 | 2000-05-08 | Phillip B. B. Moheno | Novel pterin antineoplastic agents |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
CZ20012498A3 (cs) | 1999-01-13 | 2002-08-14 | Warner-Lambert Company | Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK |
JP2002536320A (ja) | 1999-02-02 | 2002-10-29 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | プテリジン誘導体の免疫抑制作用 |
JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
JP4783532B2 (ja) * | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkのインヒビターとして有用なピラゾール組成物 |
MXPA02007957A (es) * | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
CA2407370A1 (fr) | 2000-04-24 | 2001-11-01 | Bristol-Myers Squibb Company | Heterocycles utiles en tant qu'inhibiteurs de l'enzyme impdh |
JP2004501092A (ja) * | 2000-04-28 | 2004-01-15 | バクスター ヘルスケア ソシエテ アノニム | 2−アシル−インドール誘導体および抗腫瘍剤としてのその使用 |
RU2283311C2 (ru) * | 2000-06-28 | 2006-09-10 | Астразенека Аб | Замещенные производные хиназолина и их применение в качестве ингибиторов |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4922539B2 (ja) * | 2000-09-15 | 2012-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
ZA200301696B (en) * | 2000-09-15 | 2004-04-28 | Vertex Pharma | Isoxazoles and their use as inhibitors of erk. |
DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
NZ526470A (en) * | 2000-12-21 | 2006-03-31 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
US6849634B2 (en) | 2000-12-21 | 2005-02-01 | Icagen | Potassium channel inhibitors |
DE60220642T2 (de) | 2001-01-30 | 2008-02-21 | Altachem Pharma Ltd. | Perylenequinone zur anwendung mit immunotherapeutischen mitteln |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
US6949544B2 (en) * | 2001-03-29 | 2005-09-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
CA2443487A1 (fr) * | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases |
US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
CA2446864C (fr) * | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de src et autres proteine kinases |
WO2002102800A1 (fr) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidine-4-yl) benzisoxazoles en tant qu'inhibiteurs de proteine kinases |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003000690A1 (fr) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthese de composes heterocycliques faisant appel a une technologie micro-onde |
ATE337312T1 (de) * | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
WO2003006670A2 (fr) | 2001-07-09 | 2003-01-23 | Axys Pharmaceuticals, Inc. | Derives de l'acide 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinique en tant qu'inhibiteurs du facteur viia |
FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
US6698980B2 (en) * | 2001-07-30 | 2004-03-02 | Stewart Mining Products Inc. | Rock stabilizing apparatus and method |
EP1441725A1 (fr) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases |
US6992087B2 (en) * | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
CA2467870A1 (fr) * | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Derives d'aryle-1,4-pyrazine substitues |
EP2198867A1 (fr) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Composés à base de pyrimidine utiles en tant qu'inhibiteurs de GSK-3 |
TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
EP1474400A1 (fr) | 2002-02-13 | 2004-11-10 | Axys Pharmaceuticals, Inc. | Derives 2- 5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl comme inhibiteurs du facteur viia |
WO2003078427A1 (fr) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines inhibitrices des proteines kinases |
WO2003077921A1 (fr) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles utilises comme inhibiteurs de proteine kinases |
EP1485381B8 (fr) * | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines en tant qu'inhibiteurs de proteines kinases |
DE60314603T2 (de) * | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
EP1554269A1 (fr) * | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles et thiazoles presentant des activites d'inhibition des proteines kinases |
MXPA05000754A (es) | 2002-07-17 | 2005-04-19 | Warner Lambert Co | Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib. |
CA2492387A1 (fr) | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur allosterique carboxylique de la metalloproteinase matricielle 13 avec un inhibiteur selectif de la cyclooxygenase-2 qui n'est pas un celecoxib ou un valdecoxib |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
-
2004
- 2004-12-03 AU AU2004297235A patent/AU2004297235A1/en not_active Abandoned
- 2004-12-03 EP EP04813140A patent/EP1694671A2/fr not_active Withdrawn
- 2004-12-03 JP JP2006542853A patent/JP2007513184A/ja active Pending
- 2004-12-03 CA CA002548172A patent/CA2548172A1/fr not_active Abandoned
- 2004-12-03 US US11/004,657 patent/US7592340B2/en not_active Expired - Fee Related
- 2004-12-03 WO PCT/US2004/040777 patent/WO2005056547A2/fr active Application Filing
- 2004-12-03 CN CN2004800402644A patent/CN1902193B/zh not_active Expired - Fee Related
-
2007
- 2007-07-03 HK HK07107067.6A patent/HK1099764A1/xx not_active IP Right Cessation
- 2007-11-30 JP JP2007311671A patent/JP2008069178A/ja active Pending
-
2009
- 2009-08-13 US US12/540,516 patent/US20100081657A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7592340B2 (en) | 2009-09-22 |
WO2005056547A2 (fr) | 2005-06-23 |
JP2008069178A (ja) | 2008-03-27 |
EP1694671A2 (fr) | 2006-08-30 |
AU2004297235A1 (en) | 2005-06-23 |
JP2007513184A (ja) | 2007-05-24 |
CN1902193A (zh) | 2007-01-24 |
CN1902193B (zh) | 2011-07-13 |
CA2548172A1 (fr) | 2005-06-23 |
US20100081657A1 (en) | 2010-04-01 |
US20050234064A1 (en) | 2005-10-20 |
WO2005056547A3 (fr) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1099764A1 (en) | Quinoxalines useful as inhibitors of protein kinases | |
PL377825A1 (pl) | Diaminotriazole użyteczne jako inhibitory kinaz białkowych | |
ZA200704888B (en) | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | |
PT1664043E (pt) | Composições úteis como inibidores de proteínas quinases | |
TWI372624B (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
PL1811998T3 (pl) | Triazole użyteczne jako inhibitory kinaz białkowych | |
HK1072545A1 (en) | Novel inhibitors of kinases | |
HK1160859A1 (en) | Inhibitors of tyrosine kinases | |
IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
AU2003251559A8 (en) | Heterocyclic inhibitors of kinases | |
EP1673343A4 (fr) | Composes et compositions convenant comme inhibiteurs de proteine-kinases | |
EP1670771A4 (fr) | Composes et compositions inhibant les proteines-kinases | |
EP1613595A4 (fr) | Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase | |
EP1796467A4 (fr) | Inhibiteurs imidazo{4,5-b}pyrazinone de proteines kinases | |
AU2003254053A8 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
PL1648426T3 (pl) | Pochodne benzimidazolu i ich zastosowanie jako inhibitorów kinaz białkowych | |
IL175221A0 (en) | Akt protein kinase inhibitors | |
SI2332940T1 (sl) | Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz | |
EP1877424A4 (fr) | Inhibiteurs de protéines kinases et leurs utilisations | |
EP1658290A4 (fr) | Composes et compositions servant d'inhibiteurs de la proteine kinase | |
ZA200700751B (en) | Azalndoles useful as inhibitors of protein kinases | |
EP1670780A4 (fr) | Composes et compositions utiles comme inhibiteurs de la proteine kinase | |
SI1664043T1 (sl) | Sestavki, uporabni kot zaviralci protein kinaz | |
EP1954717A4 (fr) | Inhibiteurs peptidiques de kinases abl | |
ZA200500492B (en) | Novel inhibitors of kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151203 |